Treat to Target
Session approved for 1 ASRT Category A Credit
Session approved for up to 1 AMA PRA Category 1 Credits™
This session duration is 50 minutes.
Supportive data will include review of critical factors affecting imminent risk of fracture, the relationship between bone density after osteoporosis treatment and subsequent risk of fracture, the probability of attaining bone density targets with different medications and the importance of treatment sequence.
- Discuss the rationale for considering osteoporosis treatment targets for patients at different levels of risk and how the clinical implementation of goal directed therapy affects therapeutic decision-making.
- Identify the factors associated with very high risk of fracture, including high imminent risk, and the importance of choosing therapy that rapidly reduces that risk.
- Recognize the relationship between bone density achieved after osteoporosis treatment and the subsequent risk of fracture, and the probability of attaining bone density targets with different medications and treatment sequences.
Felicia Cosman, MD
Professor of Medicine at Columbia University College of Physicians and Surgeons
Dr. Felicia Cosman is a clinical scientist, osteoporosis specialist, Professor of Medicine at Columbia University and North American Co-Editor in Chief of Osteoporosis International since 2016. She received a BA from Cornell, MD from Stony Brook, and completed internship, residency and endocrinology fellowship at Columbia University College of Physicians and Surgeons. She received the ACE Distinction in Endocrinology Award in 2019 and the ASBMR Bartter Award for clinical research in September 2020. Dr. Cosman has had many grants from NIH, DOD, MS Society, and industry and has published over 180 peer-reviewed papers and over 50 book chapters. The main focus of her research has been in the use of anabolic medications and treatment sequencing. Dr. Cosman has investigated the effect of teriparatide on biochemical markers, bone density, central and peripheral CT, bone strength by finite element analysis, and cellular action using iliac crest bone biopsy. She also studied the effect of teriparatide on bone formation in the human femoral neck in patients undergoing hip arthroplasty and performed a series of studies investigating cyclic, combination and sequential regimens of teriparatide and antiresorptive agents. Dr. Cosman has also been a major clinical investigator on multiple studies evaluating the effects of sequential therapy using romosozumab and abaloparatide. She is well known for advocating early use of anabolic treatment in very high-risk patients, optimizing treatment sequences and longterm treatment strategies, and implementing therapeutic goals for osteoporosis management.
Amgen (Self) : Advisory Board (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing); Enterabio (Self) : Consultant (Status: Ongoing); Obseva (Self) : Consultant (Status: Ongoing); Pfizer (Self) : Consultant (Status: Ongoing); Radius Health (Self) : Consultant (Status: Ongoing), Research Support (Status: Ongoing), Speaker's Bureau / Teaching Engagements (Status: Ongoing)
Rachel Pessah-Pollack, FACE (Moderator)
Clinical Associate Professor
NYU Langone Hospitals
Rachel Pessah-Pollack, M.D., F.A.C.E. is a Clinical Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at NYU Langone Health in New York City. She trained at the Mount Sinai School of Medicine in New York City, where she completed her Internal Medicine Residency and Endocrinology Fellowship and is Board Certified in Endocrinology, Diabetes & Metabolism. She was elected in 2019 to the American Association of Clinical Endocrinologists (AACE) Board of Directors for a three-year term. She has served as Chair of the AACE Clinical Practice Guidelines Oversight Committee and Chair of the AACE Women's Leadership Dinner in 2019. She served as Chair of the American College of Cardiology's (ACC) Diabetes Collaborative Registry Stakeholder Advisory Committee from 2018-2019. She has been named a New York Times Super Doctor (2017-2019) and New York Times Super Doctor Rising Star (2014-2016.) She is a frequent contributor to Health Monitor publications for patients and is on the Advisory Board of Endocrine Today. She is a coauthor of numerous peer-reviewed articles and clinical practice guidelines including the recently published AACE Postmenopausal Osteoporosis Guidelines. Dr. Pessah-Pollack specializes in metabolic bone disease and lectures nationally on the topic of postmenopausal osteoporosis. She remains actively involved in medical education and the training of endocrine fellows.
Boehringer Ingelheim/Eli Lilly (Self) : Advisory Board (Status: Ongoing); Health Monitor (Self) : Advisory Board (Status: Ongoing); Radius (Self) : Advisory Board (Status: Terminated --- 6/2020); Sanofi (Self) : Advisory Board (Status: Terminated --- 6/2020)